SCHEMBL6530087

SCHEMBL6530087

O=C(O)c1ccccc1-c1cc(=O)c2ccccc2o1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.73
POLB P06746 2/20 0.73
AKR1C3 P42330 1/20 0.66
AKR1C2 P52895 1/20 0.66
AKR1C1 Q04828 1/20 0.66
HPGD P15428 6/20 0.61
NPC1 O15118 5/20 0.61
SMN1; SMN2 Q16637 5/20 0.61
RAB9A P51151 4/20 0.61
TNKS O95271 6/20 0.61
CYP3A4 P08684 5/20 0.61
TP53 P04637 3/20 0.61
MEN1 O00255 3/20 0.61
CYP2C9 P11712 3/20 0.61
CYP2C19 P33261 3/20 0.61
KMT2A Q03164 3/20 0.61
MAPT P10636 3/20 0.61
ALOX15 P16050 3/20 0.61
TDP1 Q9NUW8 2/20 0.61
HSD17B10 Q99714 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28291729 0.87 AKR1C3 (0.64) KDM4EPOLBAKR1C3AKR1C2AKR1C1
SCHEMBL1923197 0.85 AKR1C3 (0.62) KDM4EPOLBAKR1C3AKR1C2AKR1C1
SCHEMBL23216979 0.82 AKR1C3 (0.58) KDM4EPOLBAKR1C3AKR1C2AKR1C1
SCHEMBL2209825 0.80 TSHR (0.58) KDM4EPOLBNPC1SMN1; SMN2RAB9A
SCHEMBL312255 0.80 AKR1C3 (1.00) KDM4EPOLBAKR1C3AKR1C2AKR1C1
SCHEMBL7703074 0.80 TNKS (0.75) KDM4EPOLBAKR1C3AKR1C2AKR1C1
SCHEMBL8947940 0.79 USP2 (0.58) KDM4EPOLBAKR1C3AKR1C2AKR1C1
SCHEMBL4634256 0.78 HPGD (0.73) KDM4EPOLBAKR1C3AKR1C2AKR1C1
SCHEMBL1423180 0.76 HPGD (0.67) KDM4EPOLBAKR1C3AKR1C2AKR1C1
SCHEMBL2436664 0.76 HPGD (0.67) KDM4EPOLBAKR1C3AKR1C2AKR1C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-6025211-A None JP disclosed
JP-61238783-A None JP disclosed
US-6965039-B2 7-carboxy-flavone derivatives preparation method and therapeutic use NEGMA-LERADS (FR) 2005-11-15 US disclosed
US-20040059136-A1 7-carboxy-flavone derivatives preparation method and therapeutic use NEGMA-LERADS (FR) 2004-03-25 US disclosed
EP-1212313-B1 7-CARBOXY-FLAVONE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USE NEGMA LERADS (FR) 2003-05-28 EP disclosed
EP-1212313-A1 7-CARBOXY-FLAVONE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USE Negma-Lerads (FR) 2002-06-12 EP disclosed
WO-2002028851-A1 7-CARBOXY-FLAVONE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USE NEGMA-LERADS (FR) 2002-04-11 WO disclosed
JP-H0625211-A FLAVONECARBOXYLIC ACID DERIVATIVE MITSUBISHI KASEI CORP 1994-02-01 JP disclosed
JP-S61238783-A FLAVONE CARBOXAMIDE DERIVATIVE HOKURIKU SEIYAKU CO LTD 1986-10-24 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040059136-A1 7-carboxy-flavone derivatives preparation method and therapeutic use BCOR, CYP7B1, CYP21A2 KDM4E 217/4885POLB 3199/4885AKR1C3 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.